Publications

Lindner et al. report that their findings underscore the need for sex-specific treatment strategies and more comprehensive research into biological and sociocultural factors influencing therapy persistence and reasons for discontinuation in real-world settings. Authors investigated sex differences in treatment outcomes, persistence, discontinuation reasons, and adverse events during first-line b/tsDMARD therapy.

This study observed sex differences in PsA, with women showing higher baseline disease activity and musculoskeletal burden, but lower therapy persistence, particularly with TNFi and IL17i therapies. Tailored treatment strategies are needed with regard to biologic therapy to overcome worse therapeutic outcomes in female patients with PsA.